Kane Biotech Announces Special Meeting of Shareholders

WINNIPEG, Manitoba, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announces today that on February 20, 2024, the Company will hold a special meeting of its shareholders (the “Meeting”) to consider the election of Dr. Robert Huizinga as an additional director of the Company. The information circular and other materials with respect to the Meeting will be filed on SEDAR+ by the Company in due course.

Dr. Huizinga is currently the principal of Reformation Consulting Services. He was formerly the Executive Vice-President of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) and led the clinical development of voclosporin which had first year sales of $100 million USD. Prior to that, Dr. Huizinga was the Vice President of Clinical Affairs for Isotechnika Inc, and was a clinical investigator at the University of Alberta. Dr. Huizinga holds a PhD in Organizational Leadership, a Masters in Clinical Epidemiology, holds his Nephrology certification and is a member of Sigma Theta Tau. He holds a certificate in leadership from EQUIP Leadership. Dr. Huizinga has been a member of Kane Biotech’s Scientific Advisory Board since 2018.

About Kane Biotech

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (80 patents and patents pending, trade secrets and trademarks) and products developed by the Company's own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex™, bluestem™, bluestem®, silkstem™, goldstem™, coactiv+™, coactiv+®, DermaKB™, DermaKB Biofilm™, and revyve™ are trademarks of Kane Biotech Inc. The Company is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.

Notes to Editor/References:

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedarplus.ca. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.